Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Stephen V Liu
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Emory Saint Joseph'S Hospital
Atlanta, Georgia, United States
- Emory University Hospital Midtown
Atlanta, Georgia, United States
- Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
- Wayne State University/karmanos Cancer Institute
Detroit, Michigan, United States
- Dartmouth Hitchcock Medical Center/dartmouth Cancer Center
Lebanon, New Hampshire, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Nyp/weill Cornell Medical Center
New York, New York, United States
- Wake Forest University at Clemmons
Clemmons, North Carolina, United States
- Hayworth Cancer Center
High Point, North Carolina, United States
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- University of Virginia Cancer Center
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Nov 2018
- Primary completion
- 14 Jul 2025
- Completion
- 3 Oct 2026
- Last update posted
- 7 Oct 2025
- Registered enrollment
- 51
- Registry id
- NCT03600701
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.